Conci S, Solano BLF, Novoa PA, Rivoira MÄ

Language: Spanish
References: 25
Page: 10-17
PDF size: 258.13 Kb.

ABSTRACT

Introduction: Secondary hyperparathyroidism (HPT) is a common complication of end-stage chronic kidney disease (CKD). Following kidney transplantation (KT), HPT typically resolves; however, it persists in 10 to 66% of patients one year post-KT, referred to as persistent hyperparathyroidism (HPTp), also known as tertiary HPT, increasing the risk of bone loss and fractures. Several factors may be associated with developing HPTp, but they have yet to be welldefined. Furthermore, there is no consensus on defining the PTHi levels to diagnose HPTp, with KDIGO guidelines recommending initiating treatment when PTHi is ›100 pg/ml. Objectives: To assess the prevalence of HPTp in the first year post-KT and correlate it with serum calcium (Ca), phosphate (P), alkaline phosphatase (ALP), and renal function. Analyze the risk factors for HPTp development. Materials and Methods: An observational, longitudinal, and retrospective study was conducted on patients who received KT at the Nephrology Service of Córdoba Hospital between 2010 and 2019. We included 48 patients with an average age of 42.0 ± 11.8 years and 54% male; the patient›s data were obtained from the service›s medical records. Most patients received induction therapy with basiliximab and an immunosuppressive regimen comprising calcineurin inhibitors, mycophenolate, and steroids. The analyzed variables included recipient age, gender, donor type, CKD etiology, dialysis modality, and time on dialysis. PTHi, Ca, P, and ALP levels were recorded at the time of KT, at 6 and 12 months. Renal function was evaluated at one, six, and twelve months. Descriptive statistics were used for the analysis. Group comparisons were made using the Chi-square test and t-test, with p-values ‹0.05 considered significant. Results: The most prevalent CKD etiologies were nephropathies of unknown origin (31%) and nephroangiosclerosis (19%). Twenty-five patients had PTH levels exceeding 300 pg/ml before KT. Ten patients (20%), primarily women, presented HPTp one year post-KT. Longer time on dialysis (47.9 vs. 85.6 months; p ‹ 0.01) and older recipient age (40.3 vs. 48.7 years; p ‹ 0.003) were associated with the development of HPTp. Other risk factors for HPTp included higher levels of ALP and PTHi at six months post-KT. As expected, these patients tended towards hypercalcemia (10.5 vs. 9.6 mg/dl) and hypophosphatemia (2.5 vs. 3.5 mg/dl). One year post-KT, renal function was similar in both groups, with 70% having a glomerular filtration rate between 30-60 ml/min and 30% ›60 ml/ min. Conclusion: The most significant risk factors for HPTp development post-KT were recipient age, time on dialysis, and levels of ALP and PTHi at six months post-KT. 80% of patients resolved HPT after one year of KT.Future strategies should focus on reducing waitlist time and timely management of tertiary HPT before transplantation.

REFERENCES

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison ofmortality in all patients on dialysis, patients on dialysisawaiting transplantation, and recipients of a firstcadaveric transplant. N Engl J Med. 1999;341:1725–1730.

2. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survivalin recipients of marginal cadaveric donor kidneyscompared with other recipients and wait-listedtransplant candidates. J Am Soc Nephrol. 2001;12:589–597.

3. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQIUS commentary on the 2009 KDIGO ClinicalPractice Guideline for the Diagnosis, Evaluation,and Treatment of CKD-Mineral and Bone Disorder(CKD-MBD). Am J Kidney Dis. 2010;55:773-799.

4. Moe S, Drueke T, Cunningham J, et al. Definition,evaluation, and classification of renal osteodystrophy:a position statement from kidney disease: ImprovingGlobal Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.

5. Alshayeb HM, Josephson MA, Sprague SM.CKD-mineral and bone disorder managementin kidney transplant recipients. Am J Kidney Dis.2013;61:310-25.

6. Kidney Disease: Improving Global Outcomes(KDIGO) CKD–MBD Work Group. KDIGOclinical practice guideline for the diagnosis, evaluation,prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int.2009;76 (Suppl 113): S1–S130.

7. Damasiewicz MJ, Ebeling PR. Management of mineraland bone disorders in renal transplant recipients.Nephrology (Carlton). 2017;22 Suppl 2:65-69.

8. Wolf M, Weir MR, Kopyt N, et al. A prospectivecohort study of mineral metabolism after kidneytransplantation. Transplantation 2016; 100:184-93.

9. Pihlstrom H, Dahle DO, Mjoen G et al. Increasedrisk of all-cause mortality and renal graft loss in stablerenal transplant recipients with hyperparathyroidism.Transplantation 2015; 99:351–359.

10. Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F,Brandenburg V y col. Novel insights into parathyroidhormone: report of The Parathyroid Day in ChronicKidney Disease. Clin Kidney J. 2018;12:269-28.

11. Evenepoel P, Claes K, Kuypers D et al. Natural historyof parathyroid function and calcium metabolism afterkidney transplantation: a single-center study. NephrolDial Transplant. 2004;19:1281–1287.

12. Araujo MJCLN, Ramalho JAM, Elias RM, JorgettiV, Nahas W, Custodio M, Moysés RMA, David-NetoE. Persistent hyperparathyroidism as a risk factor forlong-term graft failure: the need to discuss indicationfor parathyroidectomy. Surgery. 2018;163:1144-1150.

13. Silver, J.; Levi, R. Regulation of PTH synthesis andsecretion relevant to the management of secondaryhyperparathyroidism in chronic kidney disease. KidneyInt. Suppl. 2005,95,S8–S12.

14. Miedziaszczyk, M.; Lacka, K.; Tomczak, O.; Bajon, A.;Primke, M.; Idasiak-Piechocka, I. Systematic Reviewof the Treatment of Persistent HyperparathyroidismFollowing Kidney Transplantation. Biomedicines2023, 11, 25.

15. Rodríguez MP, Caicedo A, Huérfano MA, García PK,Berrío F, Rosselli D. Secondary hyperparathyroidismafter kidney transplant Experience of a transplantcenter. Acta Med Colomb. 2016; 41:111-115.

16. Evenepoel, P.; Claes, K.; Kuypers, D.; Maes, B.;Bammens, B.; Vanrenterghem, Y. Natural history ofparathyroid function and calcium metabolism afterkidney transplantation: A single-centre study. NephrolDial. Transplant. 2004, 19, 1281–12877-9.

17. Lou I, Foley D, Odorico SK, Leverson G,Schneider DF, Sippel R, et al. How Well Does RenalTransplantation Cure Hyperparathyroidism? AnnSurg. 2015;262:653–9.

18. Evenepoel P Recovery versus persistence of disorderedmineral metabolism in kidney transplant recipients.Semin Nephrol. 2013;33:191–203.

19. Dulfer RR, Franssen GJH, Hesselink DA, HoornEJ, van Eijck CHJ, van Ginhoven TM. Systematicreview of surgical and medical treatment for tertiaryhyperparathyroidism. Br J Surg. 2017;104:804–13.

20. KDIGO 2017 Clinical Practice Guideline Updatefor the Diagnosis, Evaluation, Prevention, andTreatment of Chronic Kidney Disease–Mineral andBone Disorder (CKD-MBD). Kidney InternationalSupplements. 2017;7,1–59.

21. Delos Santos R, Rossi A, Coyne D, Maw TT.Management of Post-transplant Hyperparathyroidismand Bone Disease. Drugs. 2019;79,501-513.

22. Sutton W, Chen X, Patel P, Karzai S, Prescott JD, SegevDL, McAdams-DeMarco M, Mathur A. Prevalenceand risk factors for tertiary hyperparathyroidism inkidney transplant recipients. Surgery. 2022; 171(1):69-76.

23. Vervloet MG, Brandenburg VM; CKD-MBDworking group of ERA-EDTA. Circulating markers ofbone turnover. J Nephrol. 2017;663-670.

24. Pihlstrom H, Dahle DO, Mjoen G. Increased riskof all-cause mortality and renal graft loss in stablerenal transplant recipients with hyperparathyroidism.Transplantation 2015; 99:351–359.

25. Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F,Brandenburg V y col. Novel insights into parathyroidhormone: report of The Parathyroid Day in ChronicKidney Disease. Clin Kidney J. 2018; 12:269-28.